Health Catalyst Inc is a leading provider of data and analytics technology for healthcare organizations, focused on improving clinical and financial outcomes through its innovative solutions. By leveraging a robust data platform, the company enables healthcare providers to aggregate, analyze, and visualize their data, facilitating better decision-making and operational efficiencies. Health Catalyst's suite of applications and services supports organizations in their journey towards value-based care by enhancing performance improvement initiatives, driving better patient outcomes, and optimizing healthcare delivery systems. Ultimately, the company's mission is to empower healthcare organizations with the insights and tools needed to transform the industry and enhance the quality of care. Read More
Shares of healthcare software provider Health Catalyst (NASDAQ:HCAT)
fell 21.5% in the afternoon session after the company reported second-quarter results that met expectations but slashed its full-year revenue forecast and provided a weak outlook for the upcoming quarter. The healthcare software provider’s revenue of $80.72 million and adjusted earnings per share of $0.04 were both in line with Wall Street estimates for the second quarter. However, investors were focused on the future, as the company projected third-quarter revenue of $75 million, which was roughly 12% below analyst expectations. Furthermore, Health Catalyst cut its full-year revenue forecast by 7.5% to $310 million. While the company did beat adjusted EBITDA estimates for the quarter and raised its full-year outlook for the metric, the significant reduction in its revenue guidance overshadowed the positive news, sending shares lower.
Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 6.3% year on year to $80.72 million. On the other hand, next quarter’s revenue guidance of $75 million was less impressive, coming in 12% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.
SALT LAKE CITY, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025.
A number of stocks jumped in the afternoon session after the Software as a Service (SaaS) sector rebounded following the sell-off in the previous trading session as a weaker-than-expected U.S. jobs report increased the probability of a Federal Reserve interest rate cut. The July Nonfarm Payrolls (NFP) report showed the U.S. economy added only 73,000 jobs, significantly below the 110,000 forecast. This, combined with downward revisions for May and June, signaled a cooling labor market to investors. In response, market expectations for a September interest rate cut by the Federal Reserve surged from roughly 40% to over 80%. A potential rate cut is generally favorable for growth sectors like technology and SaaS, as lower rates can increase the present value of their future earnings, boosting stock valuations.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Shares of healthcare software provider Health Catalyst (NASDAQ:HCAT)
jumped 6.6% in the afternoon session after the stock gained ground amid broader positive market sentiment ahead of a busy week for corporate earnings.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
SALT LAKE CITY, July 17, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its second quarter 2025 operating results on Thursday, August 7, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth.
A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on.
However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the data analytics industry, including Health Catalyst (NASDAQ:HCAT) and its peers.
Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.3% year on year to $79.41 million. On the other hand, next quarter’s revenue guidance of $80.5 million was less impressive, coming in 3.1% below analysts’ estimates. Its non-GAAP profit of $0.01 per share was in line with analysts’ consensus estimates.
A number of stocks jumped in the pre-market session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
SALT LAKE CITY, May 20, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jason Alger, Chief Financial Officer, and Jack Knight, Vice President of Investor Relations, will participate in the following upcoming investor conferences:
Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10.
However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.